

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

- 1-11. (canceled)
12. (currently amended) A method for the treatment and/or prophylaxis of inflammatory bowel disease (IBD) comprising administering a therapeutically effective amount of an inhibitor of CSF-1 activity to a patient in need thereof.
13. (original) The method according to claim 12, wherein the inhibitor is a nucleic acid.
14. (original) The method according to claim 12, wherein the inhibitor is a small molecule (NCE).
15. (currently amended) The method according to claim 12, wherein the inhibitor is an antibody or a functionally active antibody fragment or derivative ~~thereof~~.
16. (currently amended) The method according to claim 15, wherein the antibody or antibody fragment ~~thereof~~ is monoclonal, polyclonal, chimeric, ~~humanised~~ humanized or bispecific.
17. (currently amended) The method according to claim 15 ~~or claim 16 where~~ wherein the antibody fragment is a Fab, Fab', F(ab')<sub>2</sub>, scFv or epitope binding fragment ~~thereof~~.
18. (currently amended) The method according to ~~any one of claims 15-17~~ claim 15 wherein the antibody or antibody fragment ~~thereof~~ is conjugated to one or more effector molecule(s).
19. (currently amended) The method according to ~~any one of claims 15-18~~ claim 15 ~~in which~~ wherein the antibody or antibody fragment ~~thereof~~ binds to CSF-1.

20. (currently amended) The method according to ~~any one of claims 15-18~~ claim 15 in ~~which~~ wherein the antibody or antibody fragment ~~thereof~~ binds to CSF-1R.

21. (currently amended) The method according to ~~any one of claims 12-20~~ claim 12 ~~where~~ wherein the inflammatory bowel disease is Crohn's disease.

22. (currently amended) The method according to ~~any one of claims 12-20~~ claim 12 ~~where~~ wherein the inflammatory bowel disease is ulcerative colitis.

23. (currently amended) The method according to ~~any one of claims 12-22~~ claim 12 ~~where~~ wherein the inhibitor of CSF-1 activity is administered in combination with one or more other therapeutically active compounds.

24. (currently amended) The method according to claim 23 ~~in which~~ wherein the other therapeutically active compound is another anti-IBD therapeutic agent.

25. (currently amended) The method according to claim 23 ~~in which~~ wherein the other therapeutically active compound is an anti-cancer ~~therapy~~ therapeutic agent.